A.1b—A list of all required assurances that must be submitted with the plan;

A.1c—Copies of all certifications that are to be complied with and clarification about which one will have to be signed and actually submitted with the plan.

Attachment A.2 presents the statutory basis for five-year plan approval.

Attachment A.3 presents the statutory basis for exempting eligible Indian Tribes from inappropriate requirements.

★ Attachment B addresses the new CFS–101, which consists of the State Annual Budget Requests for title IV–B, subparts 1 and 2, and the State annual Summary of Child Welfare Services. The new CFS–102 is essentially an updated CWS–101 and requests some new information so States can receive their subpart 2 allotment:

Attachment B.1 provides a general orientation to the new CFS–101. Included in Attachment B.1 are:

B.1a—Information on the development of the CFS–101;

B.1b–General directions and timeframes for submission of the CFS–101.

Attachment B.2 provides instructions for filling out the three forms which constitute the CFS–101:

(Form 1) Part I: Annual Budget Request for Title IV–B, Subpart 1, Child Welfare Services. Part I is the same as the old CWS–101 Part I: Annual Budget Request;

(Form 2) Part I Supplement: Annual Budget Request for Title IV–B, Subpart 2. Part I Supplement is a new form for States to request funds from the Family Preservation and Support Services Program;

(Form 3) Part II: Annual Summary of Child and Family Services. Part II is essentially the same as the old CWS–101 Part II, except that some new information relevant to implementation of the Family Preservation and Support Services Program is being requested

Copies of all the forms are enclosed.

Submittals: The Five-Year Plan

An original and two copies of the plan must be submitted to the Administration for Children and Families (ACF) Federal Regional Office by June 30, 1995. Guidelines can be found in Attachment A.

The CFS–101

The due dates for the Annual Budget Requests and the Annual Summary of Services for FYs 1995 and 1996 vary depending upon a number of different circumstances. Explicit instructions can be found in Attachment B.

Submit the original (with original signature) and two copies to the Administration for Children and Families (ACF) Federal Regional Office.

[FR Doc. 95–11825 Filed 5–12–95; 8:45 am]

BILLING CODE 4184–01–M

Agency Information Collection Under OMB Review

Title: ACF—535 LIHEAP Quarterly Estimates

OMB No.: 0970–0037

Description: The information collected is used to develop our apportionment request for appropriated Low-Income Home Energy Assistance Programs (LIHEAP) funds and to make grant awards based on the funding needs of States and Tribes.

Respondents: State and tribal governments

Annual Number of Respondents: 55 sites

Number of responses per respondent: 1

Total annual responses: 55 sites

Hours per response: .25

Total Annual Burden Hours: 14

Additional Information: Copies of the request for approval may be obtained from Bob Sargis of the Office of Information Resource Management, ACF, by calling (202) 690–7275.

OMB Comment: Consideration will be given to comments and suggestions received within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, 725 17th Street, N.W., Washington, D.C. 20503, Attn: Ms. Wendy Taylor.

Dated: May 8, 1995.

Roberta Katson,

Acting Director, Office of Information Resource Management.

[FR Doc. 95–11826 Filed 5–12–95; 8:45 am]

BILLING CODE 4184–01–M

Food and Drug Administration

[Docket No. 95N–0109]

Animal Drug Export; Marbofloxacin

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Pfizer, Inc., has filed an application requesting approval for the export of a specific amount of the bulk form of the new drug substance marbofloxacin to France.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of animal drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Gregory S. Gates, Center for Veterinary Medicine (HFV–114), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1617.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of drugs that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802 (b)(3)(A) of the act requires that the agency publish a notice in the **Federal Register** within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Pfizer, Inc., 235 East 42d St., New York, NY 10017, has filed application number 6936 requesting approval for the export of a specific amount of the bulk form of the new drug substance marbofloxacin to France for further manufacture of the finished dosage form Marbocyl, 5 milligram Tablets (antimicrobial for treatment of dogs and cats). The tablets will then be shipped to the United Kingdom where they are approved for marketing. The application was received and filed in the Center for Veterinary Medicine on April 24, 1995, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by May 25, 1995, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Veterinary Medicine D(21 CFR 5.44).